Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?When does the patent expire on ibranceAdefovir dipivoxil discount cardIs liver function monitoring necessary with lipitor
See the DrugPatentWatch profile for natalizumab
Short answer: The patents that cover the drug natalizumab (Tysabri®) are set to expire in the mid‑2020s, with the earliest generic‑entry‑eligible date likely falling around 2027. However, a few “use” patents are still active and could keep the drug under market exclusivity a little longer.
Because biologics are subject to both patent law and FDA exclusivity, the “off‑patent” date you hear about in the press is often the date when a biosimilar could be approved and marketed.
Putting these together, most analysts predict that a biosimilar or generic version of natalizumab could reach the market between 2027 and 2029. A 2027 entry would be the earliest possible, but the
Other Questions About Natalizumab :